{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:12:45Z","timestamp":1793293965117,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>TAFRO syndrome is an acute or subacute systemic inflammatory disease with no apparent cause, presenting with fever, generalized edema, thrombocytopenia, renal damage, anemia, and organ enlargement. Interleukin-6, vascular endothelial growth factor, and other cytokines are thought to be the etiologic agents that increase vascular permeability and cause the resulting organ damage. Only few reports of renal biopsy performed in patients with TAFRO syndrome exist.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 61-year-old woman, with a history of Sjogren\u2019s syndrome, was admitted to our hospital with anasarca and abdominal distension. Based on the clinical course and various laboratory findings, we diagnosed TAFRO syndrome. Renal biopsy revealed thrombotic microangiopathy, including endothelial cell swelling, subendothelial space expansion, and mesangiolysis. She was treated with oral prednisolone and cyclosporine, with consequent resolution of anasarca, pleural effusion, and ascites, and improvement in renal function and urinary findings. The patient\u2019s platelet count also normalized after 2\u00a0months of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Given that only few reports of improvement in the systemic symptoms of TAFRO syndrome using steroids and cyclosporine exist, our study investigating the relationship between the pathogenesis of TAFRO syndrome and renal disorders, as well as treatment methods, provides valuable insights.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02886-5","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T10:03:17Z","timestamp":1658570597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["TAFRO syndrome with renal biopsy successfully treated with steroids and cyclosporine: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Takahide","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Mizusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kuragano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3960\/jslrt.53.57","volume":"53","author":"H Kawabata","year":"2013","unstructured":"Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53:57\u201361.","journal-title":"J Clin Exp Hematop"},{"key":"2886_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3960\/jslrt.53.79","volume":"53","author":"Y Masaki","year":"2013","unstructured":"Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, et al. Japanese variant of multicentric Castleman\u2019s disease associated with serositis and thrombocytopenia\u2013a report of two cases: Is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop. 2013;53:79\u201385.","journal-title":"J Clin Exp Hematop"},{"key":"2886_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","volume":"103","author":"Y Masaki","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686\u201392.","journal-title":"Int J Hematol"},{"key":"2886_CR4","doi-asserted-by":"publisher","first-page":"42316","DOI":"10.1038\/srep42316","volume":"7","author":"N Iwaki","year":"2017","unstructured":"Iwaki N, Gion Y, Kondo E, Kawano M, Masunari T, Moro H, et al. Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome. Sci Rep. 2017;7:42316.","journal-title":"Sci Rep"},{"key":"2886_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5414\/CN110290","volume":"97","author":"T Uemura","year":"2022","unstructured":"Uemura T, Matsui M, Kokubu M, Samejima KI, Tsuruya K. Renal histological continuum of TAFRO syndrome: a case report and literature review. Clin Nephrol. 2022;97:121\u20138.","journal-title":"Clin Nephrol"},{"key":"2886_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12882-019-1574-9","volume":"20","author":"Y Nagayama","year":"2019","unstructured":"Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019;20:375.","journal-title":"BMC Nephrol"},{"key":"2886_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5414\/CNCS109400","volume":"6","author":"Y Noda","year":"2018","unstructured":"Noda Y, Saka Y, Kato A, Mimura T, Naruse T. Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage. Clin Nephrol Case Stud. 2018;6:16\u201320.","journal-title":"Clin Nephrol Case Stud"},{"key":"2886_CR8","doi-asserted-by":"publisher","first-page":"747678","DOI":"10.3389\/fmed.2021.747678","volume":"8","author":"M Nagai","year":"2021","unstructured":"Nagai M, Uchida T, Yamada M, Komatsu S, Ota K, Mukae M, et al. TAFRO syndrome in a kidney transplant recipient that was diagnosed on autopsy: a case report. Front Med (Lausanne). 2021;8:747678.","journal-title":"Front Med (Lausanne)"},{"key":"2886_CR9","doi-asserted-by":"publisher","first-page":"e8216","DOI":"10.1097\/MD.0000000000008216","volume":"96","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Med (Baltim). 2017;96:e8216.","journal-title":"Med (Baltim)"},{"key":"2886_CR10","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.2169\/internalmedicine.0806-18","volume":"57","author":"S Ito","year":"2018","unstructured":"Ito S, Uchida T, Itai H, Yamashiro A, Yamagata A, Matsubara H, et al. Serial manifestation of acute kidney injury and nephrotic syndrome in a patient with TAFRO syndrome. Intern Med. 2018;57:3129\u201333.","journal-title":"Intern Med"},{"key":"2886_CR11","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ekir.2020.05.004","volume":"5","author":"H Mizuno","year":"2020","unstructured":"Mizuno H, Sawa N, Watanabe S, Ikuma D, Sekine A, Kawada M, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5:1172\u20139.","journal-title":"Kidney Int Rep"},{"key":"2886_CR12","first-page":"1244","volume":"60","author":"T Honda","year":"2018","unstructured":"Honda T, Nakamura T, Yamagata K. A case of TAFRO syndrome with thrombo-microangiopathic renal pathology and a dramatic response to corticosteroid and tocilizumab. Jpn J Nephrol. 2018;60:1244\u201351.","journal-title":"Jpn J Nephrol"},{"issue":"1","key":"2886_CR13","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1053\/j.ajkd.2003.09.023","volume":"43","author":"A Seida","year":"2004","unstructured":"Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, Okino T, Ichimura K, Yoshino T, Makino H. Multicentric Castleman\u2019s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis. 2004;43(1):E3-9.","journal-title":"Am J Kidney Dis"},{"key":"2886_CR14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1681\/ASN.2010030295","volume":"21","author":"K Sison","year":"2010","unstructured":"Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010;21:1691\u2013701.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2886_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13098-018-0363-0","volume":"3","author":"MI Zafar","year":"2018","unstructured":"Zafar MI, Mills K, Ye X, Blakely B, Min J, Kong W, Zhang N, Gou L, Regmi A, Hu SQ, Zheng J, Chen LL. Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis. Diabetol Metab Syndr. 2018;3(10):62.","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"2886_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00125-010-2034-z","volume":"54","author":"D Veron","year":"2011","unstructured":"Veron D, Bertuccio CA, Marlier A, Reidy K, Garcia AM, Jimenez J, Velazquez H, Kashgarian M, Moeckel GW, Tufro A. Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes. Diabetologia. 2011;54(5):1227\u201341.","journal-title":"Diabetologia"},{"issue":"46","key":"2886_CR17","doi-asserted-by":"publisher","first-page":"39933","DOI":"10.1074\/jbc.M111.241620","volume":"286","author":"C Bertuccio","year":"2011","unstructured":"Bertuccio C, Veron D, Aggarwal PK, Holzman L, Tufro A. Vascular endothelial growth factor receptor 2 direct interaction with nephrin links VEGF-A signals to actin in kidney podocytes. J Biol Chem. 2011;286(46):39933\u201344.","journal-title":"J Biol Chem"},{"issue":"11","key":"2886_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ki.2010.64","volume":"77","author":"D Veron","year":"2010","unstructured":"Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 2010;77(11):989\u201399.","journal-title":"Kidney Int"},{"key":"2886_CR19","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1046\/j.1523-1755.2001.00935.x","volume":"60","author":"S Suga","year":"2001","unstructured":"Suga S, Kim YG, Joly A, Puchacz E, Kang DH, Jefferson JA, et al. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int. 2001;60:1297\u2013308.","journal-title":"Kidney Int"},{"key":"2886_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129\u201336.","journal-title":"N Engl J Med"},{"key":"2886_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.xkme.2020.10.011","volume":"3","author":"K Shimada","year":"2021","unstructured":"Shimada K, Sasaki T, Okabe M, Koike K, Takahashi D, Terashima R, et al. TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies. Kidney Med. 2021;3:286\u201393.","journal-title":"Kidney Med"},{"key":"2886_CR22","first-page":"4703608","volume":"2016","author":"M Simons","year":"2016","unstructured":"Simons M, Apor E, Butera JN, Treaba DO. TAFRO syndrome associated with EBV and successful triple therapy treatment: Case report and review of the literature. Case Rep Hematol. 2016;2016:4703608.","journal-title":"Case Rep Hematol"},{"key":"2886_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bcmd.2015.06.013","volume":"55","author":"A Allegra","year":"2015","unstructured":"Allegra A, Rotondo F, Russo S, Calabr\u00f2 L, Maisano V, Bacci F, et al. Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature. Blood Cells Mol Dis. 2015;55:206\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"2886_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1620\/tjem.236.289","volume":"236","author":"Y Konishi","year":"2015","unstructured":"Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman\u2019s disease, with cyclosporine A: Possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med. 2015;236:289\u201395.","journal-title":"Tohoku J Exp Med"},{"key":"2886_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ctrv.2007.04.003","volume":"33","author":"T Petrella","year":"2007","unstructured":"Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, Melanoma Disease Site Group of Cancer Care Ontario\u2019s Program in Evidence-based Care. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev. 2007;33:484\u201396.","journal-title":"Cancer Treat Rev"},{"key":"2886_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.2177\/jsci.39.478","volume":"39","author":"N Iwanaga","year":"2016","unstructured":"Iwanaga N, Harada K, Tsuji Y, Kawahara C, Kurohama K, Izumi Y, et al. TAFRO syndrome with primary Sjogren\u2019s syndrome. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39:478\u201384 (in Japanese).","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02886-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T10:07:39Z","timestamp":1658570859000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02886-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02886-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient in the case report. Patients gave written consent for their personal or clinical information to be published in this study along with images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}